NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeoGenomics Inc (NEO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income, EPS, and gross margin, coupled with a lack of strong positive catalysts, make it a less compelling investment right now. Additionally, technical indicators and trading signals do not suggest a favorable entry point.
The MACD histogram is negative and contracting (-0.0927), indicating bearish momentum. RSI is at 22.79, suggesting the stock is approaching oversold territory but not yet signaling a clear reversal. Moving averages are converging, showing no strong trend. Key support is at 9.114, and resistance is at 10.153. The stock is trading near support levels, but there is no clear bullish signal.
Hedge funds and insiders are neutral, showing no negative sentiment.
The stock has a declining net income (-35.52% YoY), EPS (-33.33% YoY), and gross margin (-2.43% YoY). No recent news or significant trading trends from hedge funds or insiders. The stock is trading pre-market with a slight decline (-0.55%).
In Q4 2025, revenue increased by 10.56% YoY to $190.17M. However, net income dropped to -$9.88M (-35.52% YoY), EPS fell to -$0.08 (-33.33% YoY), and gross margin declined to 43.83% (-2.43% YoY). While revenue growth is a positive sign, the declining profitability metrics are concerning.
Analysts have raised price targets recently, with Piper Sandler increasing the target to $13 and TD Cowen raising it to $16. Both firms maintain positive ratings, citing strong fundamentals and expected sector normalization in 2026. However, BofA remains neutral, highlighting potential headwinds.
